Pixantrone dimaleate (BBR 2778) is under clinical development as an investigational treatment of non-Hodgkin’s lymphoma (NHL). It is a next generation antitumor aza-anthracenedione with a molecular structure similar to other topoisomerase II inhibitors, such as anthracyclines like doxorubicin.
The U.S. Food and Drug Administration (FDA) accepted for standard review our New Drug Application (NDA) with a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010.
Pixantrone has fast track status and its proposed indication is for the single-agent treatment of patients with relapsed or refractory aggressive NHL who have received two or more prior lines of therapy.
Licensed healthcare professionals in Europe treating individual patients with relapsing or refractory aggressive non-Hodgkin's lymphoma interested in pixantrone should contact:
IDIS Limited Tel: +44 (0) 1932 824 123 Fax: +44 (0) 1932 824 323 Email: internationalsales@idispharma.com